Get started
Author

Litza McKenzie

Observed names: Litza M. McKenzie, Litza Marie McKenzie
ORCID: 0000-0002-8828-8867
Observed ORCID: 0000-0002-8828-8867
OpenAlex ID: A5023491684
A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics
2019 · David L. Hava, Lisa Tan, et al. · British Journal of Clinical Pharmacology · 39
Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor
2020 · Samit R. Joshi, Disala Fernando, et al. · Pharmacology Research & Perspectives · 28
PDF
Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology
2022 · Debra Tompson, Mark Whitaker, et al. · Pharmaceutical Research · 14
PDF
Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772
2021 · Debra J. Tompson, Mark Whitaker, et al. · Pharmaceutical Research · 13
PDF
Dose Escalation Study to Assess the Pharmacokinetic Parameters of a Nano-amorphous Oral Sirolimus Formulation in Healthy Volunteers
2019 · Orsolya Basa-Dénes, Réka Angi, et al. · European Journal of Drug Metabolism and Pharmacokinetics · 8
Dose Finding and Food Effect Studies of a Novel Abiraterone Acetate Formulation for Oral Suspension in Comparison to a Reference Formulation in Healthy Male Subjects
2021 · Tamás Jordán, Orsolya Basa-Dénes, et al. · Pharmaceutics · 5
PDF
The novel rapid formulation of intravenous dantrolene (NPJ5008) versus standard dantrolene (Dantrium®)
2024 · Richard H. Ng Kwet Shing, Lucy B. Clayton, et al. · European Journal of Anaesthesiology · 4
Deferred registration - Quotient Sciences Code: QSC304026
2026 · Litza McKenzie · http://isrctn.com/
Deferred registration: Quotient Sciences Code: QSC303849
2026 · Litza McKenzie · http://isrctn.com/
Developing low-carbon metered-dose inhalers: effects of propellant HFA-152a on mucociliary clearance and bronchoconstriction in two Phase 1 randomised trials
2026 · Dave Singh, Italo Poggesi, et al. · Respiratory Medicine
Deferred registration: Quotient Sciences Code: QSC302725
2026 · Litza McKenzie · http://isrctn.com/
Phase I Study: QSC301634
2026 · Litza McKenzie, Jennifer Hart · http://isrctn.com/
A clinical trial to learn more about the absorption of radiolabeled drug LXE408, how the body breaks it down, and how quickly the body gets rid of it in healthy men
2026 · Litza McKenzie, Novartis Study Director · http://isrctn.com/
Phase I Study (QSC303441)
2025 · Litza McKenzie, Novartis Study Director · http://isrctn.com/
Phase I Study: Quotient Code QSC303166
2025 · Litza McKenzie, . Novartis Study Director · http://isrctn.com/
A study in healthy volunteers to compare a new test medicine to an already marketed medicine when injected into the veins
2025 · Litza McKenzie, Richard Ng, et al. · http://isrctn.com/
Phase I trial code: PKM17308
2023 · Litza Marie McKenzie · http://isrctn.com/
Phase I Trial: Quotient Code QSC205832
2023 · Litza McKenzie, Cecile Hauschka, et al. · http://isrctn.com/
Phase I Trial, Quotient Code: QSC205947
2023 · Litza McKenzie, Brian Sharpe, et al. · http://isrctn.com/
Phase I trial, Quotient Sciences code: QSC206403
2023 · Litza McKenzie, James Tran, et al. · http://isrctn.com/
Phase I trial Quotient Code: QSC207682
2022 · Litza McKenzie, Litza McKenzie, et al. · http://isrctn.com/
Phase I Trial, Quotient Code: QSC300320
2022 · Litza McKenzie, Richard Ng, et al. · http://isrctn.com/
Phase I trial Quotient Code QSC202600
2022 · Litza McKenzie, David Stamler, et al. · http://isrctn.com/
Phase I trial Quotient code: QSC206365
2022 · Litza McKenzie, Litza McKenzie, et al. · http://isrctn.com/
Study to compare the pharmacokinetics, safety and tolerability of the pediatric and adult branaplam formulation in healthy adults and the effect of food on the latter
2022 · Litza McKenzie · http://isrctn.com/
Works count: 33
Citation count: 111
H-index: 5
I10-index: 4
Year
Topic
Type